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Abstract
Background: Chronic granulomatous disease (CGD), an inherited disorder of the NADPH oxidase in which phagocytes are
defective in generating superoxide anion and downstream reactive oxidant intermediates (ROIs), is characterized by
recurrent bacterial and fungal infections and by excessive inflammation (e.g., inflammatory bowel disease). The mechanisms
by which NADPH oxidase regulates inflammation are not well understood.
Methodology/Principal Findings: We found that NADPH oxidase restrains inflammation by modulating redox-sensitive
innate immune pathways. When challenged with either intratracheal zymosan or LPS, NADPH oxidase-deficient p47
phox2/2
mice and gp91
phox-deficient mice developed exaggerated and progressive lung inflammation, augmented NF-kB activation,
and elevated downstream pro-inflammatory cytokines (TNF-a, IL-17, and G-CSF) compared to wildtype mice. Replacement
of functional NADPH oxidase in bone marrow-derived cells restored the normal lung inflammatory response. Studies in vivo
and in isolated macrophages demonstrated that in the absence of functional NADPH oxidase, zymosan failed to activate
Nrf2, a key redox-sensitive anti-inflammatory regulator. The triterpenoid, CDDO-Im, activated Nrf2 independently of NADPH
oxidase and reduced zymosan-induced lung inflammation in CGD mice. Consistent with these findings, zymosan-treated
peripheral blood mononuclear cells from X-linked CGD patients showed impaired Nrf2 activity and increased NF-kB
activation.
Conclusions/Significance: These studies support a model in which NADPH oxidase-dependent, redox-mediated signaling is
critical for termination of lung inflammation and suggest new potential therapeutic targets for CGD.
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Introduction
The lung is an interface where inhaled microbes and antigens
interactwithhost defensecells.Pathogenrecognitionreceptors(PRRs)
such as toll-like receptors (TLRs) sample microbial motifs and initiate
signaling that may result in NADPH oxidase activation. NADPH
oxidase activation requires translocation of the cytoplasmic subunits
p47
phox,p 6 7
phox,a n dp 4 0
phox and rac to the membrane-bound
flavocytochrome consisting of gp91
phox and p22
phox (phox, phagocyte
oxidase).NADPHoxidaseactivationleadstogenerationofsuperoxide
anion and downstream reactive oxidant intermediates (ROIs) and
activation of neutrophil antimicrobial proteases [1,2,3]. ROIs have
been implicated in the pathogenesis of lung diseases through several
mechanisms, including cellular injury and NF-kB activation [4,5].
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9631Chronic granulomatous disease (CGD) is an inherited disorder
of NADPH oxidase characterized by life-threatening bacterial and
fungal infections and by abnormally exuberant inflammatory
responses (e.g., inflammatory bowel disease) [6]. ‘‘Mulch pneu-
monitis’’ is a hyper-inflammatory response in CGD patients to
fungal pneumonia[7]. Studies in CGD patients [8,9,10,11] and
mouse models [12,13,14,15,16,17,18,19] point to excessive
inflammation in CGD resulting from intrinsic defect(s) in immune
regulation.
We evaluated whether NADPH oxidase activity would
counterbalance the immediate pro-inflammatory events that
follow PRR signaling by interacting with redox-sensitive pathways
to dampen inflammation. Using p47
phox2/2 [20] and gp91
phox-
deficient [21] mice that lack NADPH oxidase function, we show
that NADPH oxidase limits inflammation by attenuating the pro-
inflammatory transcription factor NF-kB and by activating Nrf2,
an anti-inflammatory transcription factor. Our studies demon-
strate pharmacological activation of Nrf2 as a potential therapeutic
strategy in CGD. This work identifies NADPH oxidase as a critical
regulator of innate immunity and provides novel understanding of
mechanisms that regulate lung inflammation.
Results and Discussion
NADPH Oxidase Down-Regulates Zymosan-Induced
Lung Inflammation
We asked whether NADPH oxidase, which is activated by
bacterial and fungal pathogens, would have a role in restraining
lung inflammation induced by microbial motifs. We selected
microbial products rather than live bacterial or fungal pathogens
to specifically evaluate NADPH oxidase as a regulator of
inflammation independently of its antimicrobial function; thus a
limitation of these studies is that they intentionally do not
encapsulate the complexity of in vivo infection models. Since
zymosan is a pro-inflammatory yeast cell wall product comprised
predominantly of particulate b-glucan that ligates TLR2 and is a
potent activator of NADPH oxidase via dectin-1 signaling [22], we
used intratracheal zymosan to induce sterile lung inflammation.
Lungs were harvested between 6 hours to 25 days after a single
administration of zymosan.
Wildtype (WT) mice developed mild peribronchial inflamma-
tion (Figure 1A). In contrast, p47
phox2/2 (CGD) mice developed a
robust and persistent inflammatory response following zymosan
administration (Figure 1B). The kinetics of zymosan-induced
histological lung inflammation in WT and CGD mice demonstrate
the dramatic difference between genotypes (Figure 1C). The early
inflammatory response in p47
phox2/2 mice was principally
neutrophilic (days 1 to 3). Well-defined pyogranulomatous lesions
consisting of foci of neutrophils surrounded by lymphohistiocytic
infiltrates were present on day 7 after zymosan administration. On
days 14 and 25, the neutrophilic component of the infiltrates was
reduced compared to earlier time points and the inflammation was
predominantly lymphohistiocytic. Bronchoalveolar lavage fluid
(BALF) cytology showed persistence of predominantly neutrophilic
inflammation through day 14 after zymosan administration in
p47
phox2/2 mice, whereas BALF neutrophilic leukocytosis in WT
Figure 1. p47
phox2/2 mice develop increased zymosan-induced lung inflammation compared to wildtype (WT) mice. Representative
lung histology of WT (A) and p47
phox2/2 (CGD) mice (B) at days 3, 7, 14, 25 after i.t. zymosan. All slides are H&E stained, 20x, and are representative of
at least 3 mice per genotype per time point. C) Percent of lung parenchyma with consolidation or granulomatous inflammation. Bronchoalveolar
lavage fluid (BALF) neutrophil (D) and macrophage (E) concentrations. 2-way ANOVA showed a significant difference between genotypes in % lung
inflammation (p,0.0001) and BALF neutrophil concentration (p,0.0001), with significant differences at the indicated time points by Boneferroni
post-test. *, p,0.01; **, p,0.001).
doi:10.1371/journal.pone.0009631.g001
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E). These results demonstrate that resolution of lung inflammation
is impaired by loss of NADPH oxidase activity.
NADPH Oxidase Regulates Pro-Inflammatory Cytokine
Production and NF-kB Activation
We measured a number of pro-and anti-inflammatory cytokines
present in BALF at days 1, 3 and 7 after i.t. zymosan treatment.
TNF-a, IL-17, and G-CSF levels in BALF were increased in
p47
phox2/2 mice compared to WT mice (Figure 2A). IL-1b
concentration was increased in p47
phox2/2 mice on day 3, but not
at other time points, whereas BALF levels of interferon-c, IL-2, IL-
4, IL-6, IL-10, IL-12, KC, MCP-1, MIP-2, and TGF-b were
similar between WT and p47
phox2/2 mice (data not shown).
Since NF-kB induces the expression of several pro-inflamma-
tory genes and is influenced by redox status, we evaluated whether
NF-kB activation was differentially regulated in p47
phox2/2 and
WT mice. Using p47
phox2/2/HLL and WT/HLL mice that
express luciferase under the control of an NF-kB dependent
promoter [23], we measured in vivo luciferase expression using
bioluminescence imaging. Zymosan-induced whole lung NF2kB
activation was significantly augmented in p47
phox2/2/HLL
compared to WT/HLL mice. NF-kB-dependent luciferase
expression peaked at 2 days post-zymosan in p47
phox2/2/HLL
Figure 2. Intratracheal zymosan treatment results in higher levels of pro-inflammatory cytokines and NF-kB activation in lungs of
p47
phox2/2 mice. A) BALF levels of TNF-a, IL-17, and G-CSF in wild type (WT) and p47
phox2/2 (CGD) mice administered i.t. zymosan. Note that the Y-
axes in the TNF-a and IL-17 graphs are in log-scale. The interaction of genotype (p47
phox2/2 vs. WT) and time was assessed by 2-way ANOVA and was
significant for each of the 3 cytokines (p,0.001). Bonferroni post-test was used to test for significance at each time point (*, p,0.05). B) Whole lung
NF-kB activation measured by bioluminescence imaging over the chest after i.v. luciferin in NF-kB reporter mice (p47
phox2/2/HLL and WT/HLL). C) NF-
kB dependent luciferase activity in bone marrow-derived macrophages (BMDMs) from p47
phox2/2/HLL and WT/HLL mice after in vitro stimulation
with zymosan (20 mg/ml). For (B) and (C), 2-way ANOVA indicated p,0.0001 between genotypes with significant differences at the indicated time
points by Bonferroni post-test. *, p,0.05; **, p,0.01; ***, p,0.001).
doi:10.1371/journal.pone.0009631.g002
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increased above baseline in WT/HLL mice at this time point
(Figure 2B).
Consistent with these in vivo findings, zymosan treatment also
resulted in increased NF-kB activation in isolated p47
phox2/2 bone
marrow-derived macrophages (BMDMs) compared to WT
BMDMs (Figure 2C). As expected, WT BMDMs had augmented
superoxide production in response to zymosan and PMA as
measured by chemiluminescence, whereas CGD macrophages
failed to do so (data not shown).
Whereas whole lung NF-kB activation peaked at day 2 and
returned to unstimulated levels by day 6 in p47
phox2/2/HLL mice,
histological lung inflammation continued to progress (Figure 1),
arguing that NF-kB activation in whole lungs is not simply a non-
specific marker of inflammation. These findings are consistent with
NF-kB activation having a role in initiating the early inflammatory
cascade while down-stream cytokines and additional pathways
play important roles in maintenance of persistent inflammation in
p47
phox2/2 mice. In vitro data using isolated macrophages further
support the role of NADPH oxidase as a negative regulator of
zymosan-induced NF-kB activation.
We examined whether the inflammatory dysregulation in
p47
phox2/2 mice after zymosan could be explained by differences
in surface expression of PRRs, binding of zymosan, or impaired
clearance of b-glucan. Using fluorescently tagged zymosan (Alexa
Fluor 488), no difference in zymosan binding or phagosomal
uptake in p47
phox2/2 and WT macrophages occurred. Surface
expression of TLR2 (anti-TLR2; eBioscience, San Diego, CA)
and dectin-1 (anti-Dectin-1 mAb, 2A11 was a gift from Gordon
Brown, PhD, University of Aberdeen, UK) in unstimulated
macrophages and at 15 and 60 minutes after zymosan stimulation
was similar between WT and p47
phox2/2 cells (data not shown).
We also tested whether clearance of b-glucan, the principal
component of zymosan, was defective in p47
phox2/2 mice. In fact,
levels of b-glucan in BALF (measured by Fungitell assay;
Associates of Cape Cod, East Falmouth, MA) were similar or
greater in WT mice, a finding that may reflect increased
clearance as a result of enhanced lung inflammation in
p47
phox2/2 mice (data not shown). These results point to NADPH
oxidase-regulated signaling events accounting for the differences
in the inflammatory phenotypes between WT and p47
phox2/2
mice, rather than differences at the level of binding to surface
receptors.
Since it is possible that p47
phox can modulate inflammation
independently of NADPH oxidase, we evaluated zymosan-induced
lung inflammation in X-linked gp91
phox2/ CGD mice [21]. We
selected a single time point (6 days). The histological lung
inflammatory response and inflammatory cell influx in BALF in
gp91
phox2/ mice were similar to p47
phox2/2 mice, except for a
trend towards fewer macrophages in BALF from gp91
phox2/ mice
at this time point (Figure 3A and B). Similar to p47
phox2/2 mice,
i.t. zymosan-induced lung NF-kB activation was significantly
increased in gp91
phox2/ mice compared to similarly treated WT
mice (Figure 3C). These consistent findings in two different mouse
models support the critical role of NADPH oxidase in down-
regulating inflammation as opposed to an individual phox protein
functioning independently of NADPH oxidase or an artifact
introduced during generation of one of the knockout colonies.
We next asked whether ligation of other PRRs would lead to
augmented lung inflammation and NF-kB activation in CGD
compared to WT mice as did zymosan. Lipopolysachharide (LPS),
a bacterial cell wall constituent, ligates CD14/TLR4 and causes a
redistribution of NADPH oxidase components in neutrophils that
primes the respiratory burst in response to other agents [22,24].
Similar to zymosan, i.t. treatment with LPS induced greater lung
inflammation (Figure 4A and B) and NF-kB activation (Figure 4C)
in p47
phox2/2 compared to WT mice. In addition, in vitro LPS
stimulation induced greater NF-kB activation in isolated
p47
phox2/2 macrophages compared to WT macrophages
(Figure 4D). These consistent results using microbial motifs that
ligate distinct PRRs underscore a broad role of NADPH oxidase in
down-regulating inflammation.
Figure 3. Intratracheal zymosan caused increased lung inflam-
mation and NF-kB activation, in gp91
phox-deficient (X-linked
CGD) versus wildtype mice. A) Representative lung section of
gp91
phox-deficient mouse 6 days after i.t. zymosan showing extensive
inflammation (H&E, 100x). Similarly treated wildtype (WT) mice had no
lung inflammation (not shown). B) On day 6 after i.t. zymosan, both
NADPH oxidase deficient genotypes (p47
phox2/2 and gp91
phox2/) had
similar BALF neutrophilic leukocytosis, whereas monocytes predomi-
nated in WT BALF. C) gp91
phox-deficient/HLL mice had increased whole
lung NF-kB activation compared to WT/HLL mice.
doi:10.1371/journal.pone.0009631.g003
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Stromal Cells, Is Essential to Restrain Zymosan-Induced
Lung Inflammation
Since NADPH oxidase isoforms exist in several non-hemato-
poietic cells and have diverse physiological functions [25], we
evaluated whether NADPH oxidase in hematopoietic cells is
required to restrain inflammation by generating mouse chimeras
in which either the hematopoietic or lung stromal cell population
harbor a functional NADPH oxidase. In all bone marrow
chimeras, the donor genotype determined NADPH oxidase
competence in circulating neutrophils, confirming that the
transplants were successful (Figure 5A). The lung inflammatory
response to zymosan was entirely dependent on the donor
genotype (Figure 5B and C). These results show that NADPH
oxidase in hematopoietic cells is required to restrain excessive
zymosan-induced inflammation, whereas NADPH oxidase in non-
hematopoietic lung stromal cells appears to be dispensable.
NADPH Oxidase Is Required for Zymosan-Induced Nrf2
Activation
Previous studies in cultured cells using a flavoenzyme inhibitor
have shown that NADPH oxidase can be an upstream regulator of
Nrf2 [26,27,28], a redox-sensitive transcription factor that is
critical for suppression of inflammatory responses [29]. We asked
whether zymosan activates Nrf2 and whether Nrf2 activation is
NADPH oxidase-dependent. If so, we reasoned that defective Nrf2
activation could contribute to the hyper-inflammatory phenotype
in p47
phox2/2 mice.
Typically, Cullin 3 (CUL3) directs the ubiquitination and
subsequent proteasome-dependent degradation of Nrf2
[30,31,32]. Oxidation or adduction of critical cysteine residues
on the adapter protein, Keap1, induces a conformational change
that inhibits its ability to bind to CUL3, thereby abrogating Nrf2
ubiquitination and allowing accumulation of transcriptionally
active Nrf2 in the nucleus [31,33]. NADPH oxidase-derived ROIs
could activate Nrf2 via oxidation of redox-sensitive cysteine
residues on Keap1.
In initial studies, we found that zymosan up-regulates nuclear
localization of Nrf2 in RAW264.7 cells by performing western
blots from nuclear protein extracts obtained 4 hours after zymosan
treatment. We then co-transfected epitope-tagged constructs for
Keap1 and CUL3 into RAW 264.7 macrophages and stimulated
the cells with zymosan. By co-immunoprecipitation, we found
reduced association between Keap1 and CUL3 at 4 hours after
zymosan, suggesting that zymosan activates Nrf2 by interfering
with Keap1/CUL3 interactions (data not shown).
To investigate whether Nrf2 activation is impaired in
p47
phox2/2 mice, we measured Nrf2 nuclear localization in
BMDMs stimulated with zymosan. Unstimulated p47
phox2/2 and
WT macrophages had similar recovery of Nrf2 from nuclear
extracts; however, increased nuclear Nrf2 was detected in WT but
Figure 4. CGD mice develop increased lipopolysaccharide-induced lung inflammation and NF-kB activation compared to wildtype
(WT) mice. Wildtype (WT)/HLL and p47
phox2/2 /HLL (CGD) mice were administered intratracheal (i.t.) LPS (3 mg/g per mouse). Representative lung
histology of a WT/HLL (A) and p47
phox2/2/HLL (B) mouse 6 days after i.t. LPS (H&E, 100x). Minimal to no lung inflammation was present in WT/HLL
mice, whereas mixed neutrophilic and lymphohistiocytic infiltrates involving ,10% of the lung and interstitial edema was present in p47
phox2/2/HLL
mouse lungs. Whole lung NF-kB activation (C) was augmented in p47
phox2/2/HLL mice administered i.t. LPS compared to similarly treated WT/HLL
mice (2-way ANOVA, p,0.0001, with Bonferroni post-test showing significant differences between genotypes at the indicated time points). D)
Isolated p47
phox2/2/HLL bone marrow-derived macrophages had augmented NF-kB activation in response to LPS compared to similarly treated WT/
HLL macrophages (2-way ANOVA, p,0.0001). *, p,0.05; **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0009631.g004
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phox2/2 macrophages after 1 and 4 hours of zymosan
stimulation (Figure 6A and B). The NQO1 promoter contains an
antioxidant response element (ARE), the target sequence for Nrf2,
and is known to be Nrf2-inducible. We therefore evaluated protein
levels of NQO1 in cytoplasmic extracts of p47
phox2/2 and WT
macrophages following zymosan stimulation as an indirect readout
of Nrf2 activation. Consistent with Nrf2 nuclear translocation,
NQO1 expression was induced by zymosan in WT, but not in
p47
phox2/2, macrophages (Figure 6C).
Since zymosan failed to induce Nrf2 nuclear translocation in
p47
phox2/2 macrophages, we asked whether well-characterized
electrophilic Nrf2 agonists 1-[2-cyano-3-,12-dioxooleana-1,9(11)-
dien-28-oyl]imidazole (CDDO-Im) [34] and sulforaphane [35]
were capable of activating Nrf2 in p47
phox2/2 mouse macrophag-
es. CDDO-Im and sulforaphane were both able to induce Nrf2
nuclear translocation in gp91
phox2/ and p47
phox2/2 macrophages,
whereas zymosan failed to increase Nrf2 translocation above
vehicle control (Figure 6D). These in vitro studies indicate a
stimulus-dependent defect in Nrf2 activation in NADPH oxidase-
deficient cells, suggesting that NADPH oxidase-produced ROIs
are required for Nrf2 activation following zymosan treatment but
are dispensable for electrophile-induced Nrf2 activation.
We then evaluated whether Nrf2 activation was NADPH
oxidase-dependent in vivo. We measured induction of Nrf2 activity
in whole lung nuclear protein extracts from WT, p47
phox2/2 and
gp91
phox2/ mice using an ELISA-based method that measures
binding of Nrf2 to its oligonucleotide target. Lung Nrf2 activity
was similar at baseline between WT and CGD mice, but was
increased after i.t. zymosan only in WT mice (Figure 6E). Taken
together, these studies support a role for NADPH oxidase in
activating Nrf2 and point to defective Nrf2 activation as a possible
mechanism for excessive inflammation in CGD.
CDDO-Im Attenuates the Zymosan-Stimulated
Hyper-Inflammatory Phenotype in p47
phox2/2 Mice
To evaluate the role of Nrf2 in the hyper-inflammatory
phenotype of p47
phox2/2 mice, we tested whether CDDO-Im
would attenuate zymosan-induced lung inflammation in these
mice. We performed pretreatment experiments in which intra-
peritoneal (i.p.) CDDO-Im or vehicle was administered daily from
days -1 to +2 in relation to i.t. zymosan, and lungs were harvested
on day +3. The mean percentage of lung parenchyma involved by
inflammatory cell infiltration was significantly greater in the
zymosan plus vehicle group compared to the zymosan plus
CDDO-Im group (3465% vs. 1367%, respectively; p=0.01),
based on blinded review (Figure 7A and B). Consistent with these
findings, BALF neutrophils were significantly reduced following
CDDO-Im treatment (Figure 7C). Cytokines shown to be
increased in zymosan-treated p47
phox2/2 mice compared to WT
mice, including TNF-a, IL-17, and G-CSF, were reduced in
BALF by CDDO-Im treatment (Figure 7D). In addition, BALF
levels of IL-23 (an inducer of Th17 cell expansion) and LIX (an
IL-17-stimulated chemokine [36]) were reduced by CDDO-Im
treatment. We also performed experiments to measure the impact
of CDDO-Im treatment on zymosan-induced NF-kB activation in
p47
phox2/2/HLL mice. By bioluminescence imaging, no differ-
ences were identified in NF-kB dependent luciferase activity in the
lungs of p47
phox2/2/HLL mice up to 3 days after zymosan plus
CDDO-Im compared to the zymosan plus vehicle group
(Figure 7E). In separate experiments, we found that CDDO-Im
did not affect zymosan-induced NF-kB activation in BMDM from
p47
phox2/2/HLL mice (data not shown).
As an indicator of Nrf2 activity in vivo, we measured protein
expression of NQO1 in lung homogenates. Consistent with in vitro
findings, no differences in NQO1 expression were found between
p47
phox2/2 mice with or without zymosan treatment; however,
CDDO-Im administration significantly increased NQO1 protein
levels in lungs of zymosan-treated p47
phox2/2 mice (Figure 7F and
G). Similar results were obtained using quantitative RT-PCR to
measure NQO1 mRNA expression (data not shown). In addition,
Nrf2 activity was increased by CDDO-Im (Figure 7H), which,
together with augmented NQO1 expression, shows the effective-
ness of this treatment for in vivo Nrf2 activation.
In additional studies, we used a ‘therapeutic’ model to evaluate
the effects of CDDO-Im on established lung inflammation in
p47
phox2/2 mice. In these studies, i.p. CDDO-Im or vehicle was
administered daily from days +2t o+5 in relation to i.t. zymosan,
and lungs were harvested on day +6. Pyogranulomatous lesions
involving approximately 40% of the lung, characterized by a
central collection of neutrophils surrounded by lymphohistiocytic
inflammation, occurred in mice that received zymosan and vehicle
(Figure 8A–D). In contrast, mice administered zymosan and
CDDO-Im had inflammatory infiltrates limited to ,10% of the
lung. The remaining areas of infiltrate in zymosan-treated mice in
the CDDO-Im group contained pyknotic cells and inflammatory
debris, with few viable cells. These apoptotic inflammatory cells
were positive for cleaved (activated) caspase-3 immunostaining
(Figure 8E–G), suggesting that CDDO-Im treatment induces
inflammatory cell apoptosis when given after the onset of
inflammation in p47
phox2/2 mice. Taken together, these results
show p47
phox2/2 mice can be rescued from hyper-inflammatory
responses by pharmacological NADPH oxidase-independent
interventions targeting the Nrf2 pathway.
Nrf2-Deficient Mice Have an Inflammatory Response
Intermediate between WT and p47
phox2/2 Mice
As Nrf2 activity is critical for the suppression of hyper-
inflammatory responses and our studies indicated that Nrf2 is
activated by NADPH oxidase in vivo, we asked whether Nrf2
2/2
mice would have a hyper-inflammatory phenotype similar to
p47
phox2/2 mice. Nrf2
2/2 mice were crossed with NF-kB reporter
(HLL) mice and compared to WT/HLL reporter mice after
Figure 5. Bone marrow chimera experiments demonstrate that NADPH oxidase in hematopoietic cells, but not lung stromal cells, is
required to restrain zymosan-induced lung inflammation. Wild type (WT) and p47
phox2/2 (CGD) mice were administered myeloablative total
body irradiation, and rescued with marrow-derived WT or p47
phox2/2 donor cells. The transplants were as follows: WT donor/CGD recipient (n=3);
CGD donor/WT recipient (n=3); WT donor/WT recipient (n=2); CGD donor/CGD recipient (n=2); the latter two transplants were performed as
specificity controls for artifacts introduced by transplantation. Recipient mice were administered i.t. zymosan at 31 days after transplant. Seven days
later, peripheral blood and lungs were harvested. A) NADPH oxidase activity in peripheral neutrophils of transplanted mice was evaluated using the
fluorescent probe, dihydrorhodamine 123 (DHR). In a representative experiment, neutrophils were unstimulated (top row) or stimulated with PMA
(100 ng/ml) (bottom row) to activate NADPH oxidase. Hydrogen peroxide, a metabolite of NADPH oxidase activation, activates DHR fluorescence. In
all transplants, the donor genotype determined NADPH oxidase competence. B) Representative lung histology (H&E, 40x) and C) percent of lung
parenchyma with consolidation or granulomatous inflammation in transplanted mice at day 7 after i.t. zymosan administration. Percent lung
inflammation was significantly greater in transplanted mice with CGD compared to wildtype donors (abbreviated, ‘‘D’’ in the figure) (unpaired t-test,
p,0.0001), whereas recipient (abbreviated, ‘‘R’’ in the figure) genotype had no effect on the inflammatory response.
doi:10.1371/journal.pone.0009631.g005
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2/2/HLL mice, histological
evidence of lung inflammation was more prominent than in WT/
HLL mice at day 3 after zymosan (Figure 9A–C). In Nrf2
2/2/
HLL mice, the neutrophilic influx in BALF was significantly
greater than in WT/HLL mice at day 3 after zymosan, but abated
by day 6 (Figure 9D). Lung NF-kB activation was similar between
Nrf2
2/2/HLL and WT/HLL mice (Figure 9E). These results
suggest that Nrf2 is primarily required for early control of
zymosan-induced inflammation and does not appear to affect NF-
kB activation. Taken together, these results point to activation of
Nrf2 as being one, but not the only, pathway by which NADPH
oxidase regulates inflammation.
Since CDDO-Im can affect both Nrf2-dependent and -
independent pathways [37], we asked whether CDDO-Im would
dampen inflammation in Nrf22/2 mice. Histological lung
inflammation was similar at day 3 after i.t. zymosan administration
in Nrf22/2 mice that received i.p. CDDO-Im (n=7) versus
vehicle (n=8) from days 21t o+2 in relation to zymosan (data not
shown), lending support to the notion that CDDO-Im attenuates
inflammation in CGD mice primarily through Nrf2 activation.
NADPH Oxidase Regulates Nrf2 and NF-kB Activation in
Human Peripheral Blood Mononuclear Cells
We next asked whether NADPH oxidase influences Nrf2 and
NF-kB activation in human cells by studying purified peripheral
blood mononuclear cells (PBMCs) from normal donors and X-
linked CGD patients. As shown in Figure 10A, zymosan-induced
Nrf2 activation was uniformly defective in CGD PBMCs. In
contrast, NF-kB activation from the same nuclear extracts was
augmented in zymosan-stimulated CGD PBMCs compared to
normal donor PBMCs (Figure 10B). Thus, our studies using
human PBMCs were consistent with mouse data, and further
support a key role for NADPH oxidase in regulating signaling
through Nrf2 and NF-kB pathways.
The principal function of NADPH oxidase is to generate ROIs
and activate neutrophil granular proteases that kill invading
pathogens. The second and less recognized function of NADPH
oxidase is to counterbalance these early pro-inflammatory events
to limit tissue injury. Indeed, our studies suggest that inflammation
may not be passively self-limited and that activation of anti-
inflammatory pathways is required to protect the host from
excessive inflammation. Consistent with studies in mice, NADPH
oxidase activates Nrf2 while restraining NF-kB activation in
human PBMCs. We propose a model in which NADPH oxidase-
derived ROIs play a central role in limiting microbial ligand-
induced inflammation by interacting in parallel with redox-
sensitive targets that regulate NF-kB and Nrf2 activation.
Our results in Nrf2
2/2 mice are consistent with other studies
demonstrating a hyper-inflammatory phenotype [29], including
Figure 6. Zymosan-induced Nrf2 nuclear translocation is
NADPH oxidase-dependent in isolated macrophages and in
vivo. Wild type (WT) and p47
phox2/2 (CGD) bone marrow-derived
macrophages (BMDMs) cultured in DMEM media with 10% serum were
stimulated with zymosan (20 m/ml). A) Western blot for Nrf2 and Tata
box binding protein (TBP) in nuclear fractions of BMDMs from
p47
phox2/2 and WT mice at baseline, 1, 4, and 24 hours after zymosan.
B) Densitometry from 3 separate experiments. p,.05 by ANOVA using
Tukey post-test. C) Western blot showing expression of NQO1 in
cytoplasmic extracts. D) Western blot for nuclear Nrf2 from gp91
phox2/
and p47
phox2/2 macrophages treated with vehicle, zymosan (20 mg/ml),
or the Nrf2 agonist electrophiles, CDDO-Im (1.0 mM) or sulforaphane
(50 mM), for 4 hours. E) Nrf2 DNA binding activity of lung nuclear
extracts in unstimulated (baseline) mice and 6 days after i.t. zymosan.
n=326 mice per group. Lung Nrf2 binding activity in zymosan-
stimulated WT mice was significantly greater than that in unstimulated
WT mice (student’s t-test, p,0.05), whereas zymosan treatment had no
effect on lung Nrf2 activation in CGD mice.
doi:10.1371/journal.pone.0009631.g006
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PLoS ONE | www.plosone.org 8 March 2010 | Volume 5 | Issue 3 | e9631Figure 7. The triterpenoid, CDDO-Im, a Nrf2 inducer, reduces zymosan-induced lung inflammation and pro-inflammatory BALF
cytokines in p47
phox2/2 mice. CDDO-Im (0.2 mg/mouse by i.p. injection) or vehicle (control) was administered daily to p47
phox2/2 mice from day
21t o+2 in relation to i.t. zymosan, and BALF and lungs were harvested on day +3. Representative H&E stained lung sections of p47
phox2/2 mice
administered zymosan plus vehicle (A) or zymosan plus CDDO-Im (B). Neutrophil (C) and cytokine (D) concentrations were assessed in BALF obtained
at day 3 after zymosan treatment. Significant differences were observed for neutrophils (p=0.03), IL-23 (p=0.008), IL-17 (p=0.02), TNF-a (p=0.02),
and LIX (p=0.03) (Mann-Whitney two-tailed test). E) Lung NF-kB activation, measured by bioluminescence, was similar in p47
phox2/2 /HLL mice
administered zymosan plus CDDO-Im versus zymosan plus vehicle (Two-way ANOVA, p=NS). F) Representative Western blot of lung homogenates
for NQO1 and (G) densitometry (normalized to b-actin) (G) for 3 mice per genotype per treatment (p,.05 by ANOVA using Tukey post-test).
Untreated = no experimental manipulation; zymosan = i.t. zymosan plus i.p. vehicle; zymosan + CDDO-Im = i.t. zymosan plus i.p. CDDO-Im. H)
Measurement of Nrf2 activity by TransAM
TM ELISA from whole lung nuclear protein extracts from p47
phox2/2 mice treated with zymosan plus vehicle
or zymosan plus CDDO-Im. Results are presented as increase over background O.D. measurement in lung nuclear protein samples from Nrf2
2/2 mice
(p,.05 using unpaired t-test).
doi:10.1371/journal.pone.0009631.g007
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LPS challenge [38,39]. Activation of Nrf2 likely mitigates ROI-
induced inflammation and cellular injury [40,41,42,43,44,45].
While our data point to Nrf2 as an important anti-inflammatory
regulator activated by NADPH oxidase, the intensity and duration
of inflammation were greater in CGD compared to Nrf2
2/2 mice,
arguing that dysregulation of Nrf2-independent pathways also
contribute to excessive inflammation in CGD. That CDDO-Im
activates Nrf2 independently of NADPH oxidase and limits
inflammation suggests that Nrf2 activation may be a promising
therapeutic strategy in controlling inflammatory complications in
CGD. CDDO-Im may also have Nrf2-independent anti-inflam-
matory effects [34,37,46,47,48]. Use of double knockout CGD x
Nrf22/2 mice will clarify whether the anti-inflammatory effect of
CDDO-Im is Nrf2-specific.
In addition to defective Nrf2 activation, failure to down-regulate
NF-kB activation likely contributes to the exaggerated inflamma-
tory response in CGD. Zymosan and LPS treatment result in a
marked increase and prolongation of NF-kB activation in the
lungs of p47
phox2/2 mice and in isolated macrophages. CDDO-Im
treatment increased lung Nrf2, but not NF-kB, activation, and
NF-kB activation was not altered in zymosan-treated Nrf22/2
mice. Together, these findings suggest that NADPH oxidase
regulates Nrf2 and NF-kB signaling in parallel to restrain
inflammatory signaling induced by PRR activation. Other studies
show the potential for cross-regulation of NF-kB and Nrf2
pathways [49,50]. Indeed, it was recently shown that Keap1
binds to, and is required for, Cullin 3-based ubiquitination of
IKKbeta, leading to downregulation of NF-kB [51].
Our findings are consistent with prior studies of human CGD
PMBCs in which expression of NF-kB-dependent pro-inflamma-
tory cytokines was increased following treatment with LPS [10,11].
In addition, CGD mice have greater cigarette smoke-induced lung
injury and NF-kB activation compared to WT mice [18]. Using
acatalasemic mice, Zmijewski et al. [52] showed that H2O2
reduced NF-kB activation in neutrophils and diminished LPS-
induced lung injury in mice. In contrast, we previously reported
that early activation of NF-kB was reduced in the lungs of CGD
mice treated with i.p. LPS [53] compared to wildtype mice,
although inflammation was similar. The difference in results
between our previous study [53] and the current work may be
related to the route of LPS administration (i.p. versus i.t. in the
current study), time of measurement of lung NF-kB activation in
relation to LPS administration (90 minutes versus later time points
in the current study), and the assay used to measure in vivo NF-kB
activation (gel shift assay, which measures the presence of NF-kB
Figure 8. CDDO-Im reduces zymosan-induced lung inflammation in p47
phox2/2 mice in therapeutic studies by induction of
apoptosis. CDDO-Im (i.p. 0.2 mg/mouse) or vehicle was administered daily from days 2 to 5 and lungs were harvested on day 6 in relation to i.t.
zymosan administration. A) Lung section of a p47
phox2/2 mouse administered zymosan and vehicle shows well-defined granulomatous lesions
occupying approximately 40% of the lung (H&E, 20x). B) Higher magnification (400x) shows dense cellular granulomata composed of neutrophils and
lymphohistiocytic infiltrates in mouse treated with zymosan and vehicle. C) In contrast, scant areas of inflammation were present in the lungs of
p47
phox2/2 mice administered zymosan and CDDO-Im (H&E, 20x). D) At higher magnification (400x), small foci of degraded inflammatory cells were
observed in CDDO-Im treated p47
phox2/2 mice. E–G) Cleaved caspase-3 immunostaining was augmented in lungs of p47
phox2/2 mice administered
zymosan and CDDO-Im compared to zymosan and vehicle. E) Lung section of zymosan and vehicle-treated mouse shows dense inflammatory lesions
with occasional apoptosis (H&E, 200x). F) Lung section of zymosan and CDDO-Im-treated mouse shows sparse areas of inflammation composed of
apoptotic cells that are positive (brown staining) for cleaved caspase-3 (H&E, 200x). G) Same section as B with rabbit isotype shows background
staining within alveolar epithelial cells, but not in areas of inflammation (H&E, 200x). Addition of blocking peptide eliminated anti-cleaved caspase-3
staining with the exception of background activity, confirming specificity of staining (data not shown). Sections are representative of 4 p47
phox2/2
mice per treatment group.
doi:10.1371/journal.pone.0009631.g008
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NF-kB-driven transcriptional activity in the current study). Other
previous studies found that hepatic NF-kB activation and injury
were reduced in CGD compared to WT mice after exposure to
toxins [54,55]. Together, these results underscore the complexity
of the interaction of ROIs and NF-kB activation that is likely
influenced by the specific stimulus, site of inflammation, kinetics of
ROI generation, and numerous redox-sensitive targets that can
activate [56] or inactivate [57] NF-kB.
In summary, our studies elucidate an under-appreciated role for
ROIs in termination of innate immune responses through
regulation of crucial intracellular signaling pathways. We and
others have previously shown specific roles for NADPH oxidase in
regulating neutrophil-endothelial cell interactions [58] and
dendritic cell and T-cell phenotypes [16,59,60,61,62]. Romani
et al. [16] demonstrated a central role of NADPH oxidase in
determining the balance between Th17 and regulatory T-cell
development through activation of tryptophan catabolism. These
studies together with our current results show that NADPH
oxidase calibrates immune homeostasis at multiple levels.
Therefore, it is not surprising that attempts at antioxidant therapy
to reduce tissue inflammation and injury have been unsuccessful.
Manipulation of critical oxidant-regulated signaling pathways, like
Nrf2, may be a more promising approach for prevention and
treatment of inflammatory lung injury [63] and other disorders of
inflammation. In addition, treatments that enhance Nrf2 activity
could be beneficial for treating inflammatory complications of
CGD.
Materials and Methods
Mice
Mice with a targeted disruption of the p47
phox gene have a
defective NADPH oxidase, rendering phagocytes incapable of
generating measurable superoxide [20]. p47
phox2/2 mice were
derived from C57BL/6 and 129 intercrosses, and were back-
crossed 14 generations in the C57BL/6 background. Age and sex-
matched C57BL/6 WT mice were used as controls. Nrf2
2/2 mice
were generated from C57BL/6 and 129 intercrosses as previously
described [64], and were backcrossed 9 generations in the
Figure 9. Nrf2
2/2 mice develop increased i.t. zymosan-induced inflammation compared to wild type (WT) mice. A) Representative lung
of WT mouse at day 3 after zymosan showing no inflammation (H&E, 20x). B) Nrf2
2/2 mouse lung showing approximately 15% of lung involved with
inflammatory infiltrates at day 3 after zymosan (H&E, 20x). C) Higher power magnification (200x) showing a predominantly histiocytic alveolar
infiltrate with scattered foci of neutrophils and apoptotic cells in the lung of an Nrf2
2/2 mouse. The above is representative of 3 mice per genotype.
D) BALF neutrophilic leukocytosis was significantly greater in Nrf2
2/2 versus WT mice at 3 days after zymosan. By day 6, the BALF neutrophil count
was similar in both genotypes. There was no significant difference in the BALF macrophage concentration. E) Zymosan-induced lung NF-kB activation
was similar in WT/HLL (n=6) and Nrf2
2/2/HLL (n=7) mice (Two-way ANOVA, p=NS).
doi:10.1371/journal.pone.0009631.g009
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controls. X-linked (gp91
phox-deficient) mice were generated by
Pollack et al. [21] We crossbred p47
phox2/2 mice with NF-kB
HIV-LTR/luciferase (HLL) reporter mice (p47
phox2/2 /HLL) as
previously described [23]. Nrf2
2/2/HLL mice were derived in a
similar fashion. This system enables visualization of NF-kB
activation longitudinally at the level of the whole mouse and
isolated organs and cells. WT and p47
phox2/2 bone marrow-
derived macrophages (BMDMs) from these mice were generated
as previously described [23]. Mice were maintained under specific
pathogen free conditions and all procedures performed on animals
were approved by the Institutional Animal Care and Use
Committee at Roswell Park Cancer Institute and Vanderbilt
University, and complied with all state, federal, and NIH
regulations.
Intratracheal Zymosan Administration
Zymosan (Sigma, St. Louis, MO) was diluted to a concentration
of 2.5 mg/ml in saline, sonicated until the particles were
suspended homogenously and frozen at 220uC. Prior to use, the
zymosan stock was diluted to 0.8 mg/mL and autoclaved to
ensure sterility. Mice were anesthetized with i.p. injections of
Avertin (380 mg/kg). Mice were restrained, hair plucked from the
throat and the area cleansed with betadine and alcohol. A medial
cut was made in the skin above the trachea followed by a medial
cut in the tracheal sheath. A BD Insyte (BD, Franklin Lakes, NJ)
cannula was inserted into the trachea just above the bifurcation
and 25 ul of the zymosan suspension followed by 25 ml of air were
injected. The incision was closed with a suture. Mice were given
1 ml of sterile PBS IP for re-hydration, placed on a heating pad
and monitored for recovery.
Bioluminescence Imaging
Mice were anesthetized, received 1 mg of D-luciferin retro-
orbitally, and were imaged as described previously [23], in an
IVIS cooled charged coupled device (Xenogen Corporation,
Alameda, CA). Data were collected and analyzed using Living
Image v.2.50 (Xenogen Corporation, Alameda, CA) and IgorPro
(Wavemetrics, lake Oswego, OR) software.
CDDO-Im (1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-
oyl]imidazole)
CDDO-Im is a semi-synthetic triterpenoid that potently induces
Nrf2 activity[34]. For each experiment, CDDO-Im was dissolved
in a 10% DMSO 10% cremaphor-EL PBS solution as previously
described [39]. Intraperitoneal CDDO-Im (0.2 mg/mouse per
day) or vehicle was administered at different times in relation to
zymosan challenge.
Cytokine and Chemokine Measurement
Mice were killed by CO2 asphyxiation, and bronchoalveolar
lavage (BAL) was performed using a total of 2 ml of cold saline per
animal. BALF IL-23 and LIX (a neutrophil chemokine) were
assessed by ELISA per the manufacturer’s instructions
(eBioscience, San Diego, CA and R&D Systems, Minneapolis,
MN, respectively). All other cytokines and chemokines were
measured at the Roswell Park Cancer Institute core facility flow
cytometry laboratory using the multiplexed flow cytometry assay
in which several cytokines can be quantitated simultaneously on
the same sample. The Luminex 100 platform is used to acquire
data from soluble bead arrays in which each bead set has a
separate capture reagent attached to the surface that is directed
against a single cytokine or chemokine.
Lung Histopathology
After sacrifice and bronchoalveolar lavage, mouse lungs were
infused with 10% neutral buffered formalin via the trachea.
Parrafin-embedded sections were prepared and stained with
hematoxylin and eosin (H&E). The percentage of lung involved
by granulomatous or consolidative inflammation was scored in
each mouse as follows: 0%, 5%, 10%, and then by 10%
increments (e.g., 20%, 30%, 40%, etc.). The predominant
inflammatory cell type was scored as neutropilic or lymphohistio-
cytic. Histopathology was assessed by one of us (BHS) in a blinded
fashion.
To evaluate for apoptosis, immunohistochemistry to detect
cleaved caspase-3 on paraffin-embedded sections was performed.
Activation of caspase-3 requires proteolytic cleavage of its inactive
zymogen. Cleaved caspase-3 (Asp175) polyclonal antibody (Cell
Signaling, Danvers, MA) detects the large fragment of activated
caspase-3 resulting from cleavage adjacent to Asp175. The cleaved
caspase-3 antibody (0.33 mg/ml) was applied to slides for 1 hour.
Rabbit IgG isotype and blocking peptide were used as specificity
controls. A biotinylated secondary anti-rabbit antibody followed
Figure 10. NADPH oxidase augments Nrf2 activation and
restrains NF-kB activation in human PBMCs. PBMCs from normal
donors (n=8) and X-linked CGD patients (n=5) were stimulated with
zymosan (20 mg/ml). A) Nrf2 activation. B) NF-kB activation. *, p,0.05
comparing normal donor and CGD PBMCs.
doi:10.1371/journal.pone.0009631.g010
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and diaminobenzidine-based peroxidase substrate were added per
the manufacturer’s instruction (Vector Labs, Burlingame, CA),
and counterstained with hematoxylin. The color reaction product
results in brown staining.
Bone Marrow Transplantation
Donor mice were sacrificed using cervical dislocation to ensure
the collection of unadulterated material. Next, femurs and tibias
were removed, the tips excised, and the bone marrow flushed out
using cold 0.1% BSA solution in PBS. Bone marrow cells were
then washed and resuspended in cold PBS. Recipient mice
received myeloablative conditioning with 12Gy of
137Cs c total
body irradiation (0.74Gy/min) split 6Gy a day for two days. Eight
hours after the final radiation dose, mice were injected in the tail
vein with the donor bone marrow cells (1610
6 cells per recipient
mouse). Recipient mice were administered i.t. zymosan at 31 days
after transplant. Seven days later, peripheral blood and lungs were
harvested. NADPH oxidase activity in peripheral neutrophils of
transplanted mice was evaluated using the fluorescent probe,
dihydrorhodamine 123 (DHR), as previously described [65].
Nuclear Protein Extraction
At the indicated time points, samples were placed on ice, washed
withPBS,andcytoplasmicandnuclear extractswereobtained using
the NE-PER kit (Pierce, Rockford, IL) in the presence of Complete
mini, EDTA-free protease inhibitor cocktail (Roche Diagnostics,
Switzerland) at 4uC. Then samples stored at 280uC.
Analysis of Nrf2 Activation
Western blot analysis of nuclear protein fractions was performed
by Odyssey system (LI-COR Bioscience, Nebraska USA), using
antibodies specific for Nrf2, TBP, beta-actin (Santa Cruz
Technology), NQO1 (Cell Signaling Technology). In whole lung
nuclear protein extracts, Nrf2 was measured by the TransAM
Nrf2 ELISA (Active Motif, Carlsbad, CA) using the manufacturers
instructions.
PBMCs from CGD Patients and Normal Donors
Whole blood from X-linked CGD patients and normal donors
were collected at the NIH Clinical Center in heparinized tubes
and processed immediately. Serum was obtained from a distinct
healthy donor in serum separator tubes, aliquoted, and frozen at
220uC until ready for use. Cell culture media was prepared from
RPMI 1640 supplemented with 2 mM l-glutamine, 100 U of
penicillin/mL, 100 mg streptomycin/mL, 10 mM HEPES buffer,
and 10% donor serum, and filter sterilized. Zymosan (Sigma) was
re-suspended in sterile filtered sodium chloride 0.85% (Quality
Biologicals), autoclaved, and kept at 4uC until ready for use.
Whole blood from each donor was diluted in a 1:1 ratio with
HBSS without divalent cations. PBMCs were collected following
standard separation on Lymphocyte-Separation medium (Media-
tech). The PBMC pellet underwent hypotonic lysis with ACK
Lysing buffer (Quality Biologicals) to remove erythrocytes, then
washed twice with HBSS and re-suspended in cell culture media.
PBMCs were enumerated by hemacytometer and confirmed
.95% viable by trypan blue exclusion. PBMCs from each subject
were inoculated in duplicate into 6 well plates at 3610
6 cells/mL,
allowed to adhere for 2 hours at 37uCi n5 %C O 2, then stimulated
with zymosan (20 mg/ml), and incubated at 37uCi n5 %C O 2.
After 1 and 4 hours of stimulation, cell culture medium was
removed, each well was washed twice in phosphate-buffered
saline, and the plate was frozen at 280uC until ready for nuclear
protein extraction. Nuclear extracts were isolated, and Nrf2
activity was measured by the TransAM Nrf2 ELISA, using the
same methods as mouse samples. NF-kB activation in nuclear
extracts was measured by relA (p65) DNA binding using the
TransAM NF-kB ELISA kit. All subjects gave written informed
consent for research testing under approved protocols of the NIH.
Statistics
Prism software was used for statistical analysis and to display
graphical data. Inter-group comparisons were made using the
non-parametric Mann-Whitney method. A p-value of ,0.05 was
considered statistically significant. For time-course experiments,
two-way ANOVA with Bonferroni post-testing at individual time
points was used.
Acknowledgments
We thank Vivian Siegel, PhD, Vanderbilt University School of Medicine,
for reviewing the manuscript and providing helpful comments.
Author Contributions
Conceived and designed the experiments: BS MF TSB. Performed the
experiments: BS WH JB MJ ZB JF CD MC DV. Analyzed the data: BS
WH JB MJ ZB JF CD RV FY MC PW HM JWC MBS JC DV SH LR SG
MF TSB. Contributed reagents/materials/analysis tools: PW HM MBS
JC. Wrote the paper: BS.
References
1. Reeves EP, Lu H, Jacobs HL, Messina CG, Bolsover S, et al. (2002) Killing
activity of neutrophils is mediated through activation of proteases by K+ flux.
Nature 416: 291–297.
2. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, et al. (2007) Novel cell
death program leads to neutrophil extracellular traps. J Cell Biol 176: 231–241.
3. Bianchi M, Hakkim A, Brinkmann V, Siler U, Seger RA, et al. (2009)
Restoration of NET formation by gene therapy in CGD controls aspergillosis.
Blood 114: 2619–2622.
4. Tasaka S, Amaya F, Hashimoto S, Ishizaka A (2008) Roles of oxidants and
redox signaling in the pathogenesis of acute respiratory distress syndrome.
Antioxid Redox Signal 10: 739–753.
5. Rahman I, Kilty I (2006) Antioxidant therapeutic targets in COPD. Curr Drug
Targets 7: 707–720.
6. Marciano BE, Rosenzweig SD, Kleiner DE, Anderson VL, Darnell DN, et al.
(2004) Gastrointestinal involvement in chronic granulomatous disease. Pediatrics
114: 462–468.
7. Siddiqui S, Anderson VL, Hilligoss DM, Abinun M, Kuijpers TW, et al. (2007)
Fulminant mulch pneumonitis: an emergency presentation of chronic granulo-
matous disease. Clin Infect Dis 45: 673–681.
8. Gallin JI, Buescher ES (1983) Abnormal regulation of inflammatory skin
responses in male patients with chronic granulomatous disease. Inflammation 7:
227–232.
9. Lekstrom-Himes JA, Kuhns DB, Alvord WG, Gallin JI (2005) Inhibition of
human neutrophil IL-8 production by hydrogen peroxide and dysregulation in
chronic granulomatous disease. J Immunol 174: 411–417.
10. Brown KL, Bylund J, Macdonald KL, Song-Zhao GX, Elliott MR, et al. (2008)
ROS-deficient monocytes have aberrant gene expression that correlates with
inflammatory disorders of chronic granulomatous disease. Clin Immunol.
11. Bylund J, Macdonald KL, Brown KL, Mydel P, Collins LV, et al. (2007)
Enhanced inflammatory responses of chronic granulomatous disease leukocytes
involve ROS-independent activation of NF-kappa B. Eur J Immunol 37:
1087–1096.
12. Morgenstern DE, Gifford MA, Li LL, Doerschuk CM, Dinauer MC (1997)
Absence of respiratory burst in X-linked chronic granulomatous disease mice
leads to abnormalities in both host defense and inflammatory response to
Aspergillus fumigatus. J Exp Med 185: 207–218.
13. Segal BH, Kuhns DB, Ding L, Gallin JI, Holland SM (2002) Thioglycollate
peritonitis in mice lacking C5, 5-lipoxygenase, or p47(phox): complement,
leukotrienes, and reactive oxidants in acute inflammation. J Leukoc Biol 71:
410–416.
14. Segal BH, Davidson BA, Hutson AD, Russo TA, Holm BA, et al. (2007)
Acid aspiration-induced lung inflammation and injury are exacerbated in
NADPH oxidase-deficient mice. Am J Physiol Lung Cell Mol Physiol 292:
L760–768.
NADPH Oxidase and Inflammation
PLoS ONE | www.plosone.org 13 March 2010 | Volume 5 | Issue 3 | e963115. van de Loo FA, Bennink MB, Arntz OJ, Smeets RL, Lubberts E, et al. (2003)
Deficiency of NADPH oxidase components p47phox and gp91phox caused
granulomatous synovitis and increased connective tissue destruction in
experimental arthritis models. Am J Pathol 163: 1525–1537.
16. Romani L, Fallarino F, De Luca A, Montagnoli C, D’Angelo C, et al. (2008)
Defective tryptophan catabolism underlies inflammation in mouse chronic
granulomatous disease. Nature 451: 211–215.
17. Schappi M, Deffert C, Fiette L, Gavazzi G, Herrmann F, et al. (2008) Branched
fungal beta-glucan causes hyperinflammation and necrosis in phagocyte
NADPH oxidase-deficient mice. J Pathol 214: 434–444.
18. Yao H, Edirisinghe I, Yang SR, Rajendrasozhan S, Kode A, et al. (2008)
Genetic ablation of NADPH oxidase enhances susceptibility to cigarette smoke-
induced lung inflammation and emphysema in mice. Am J Pathol 172:
1222–1237.
19. Gao XP, Standiford TJ, Rahman A, Newstead M, Holland SM, et al. (2002)
Role of NADPH oxidase in the mechanism of lung neutrophil sequestration and
microvessel injury induced by Gram-negative sepsis: studies in p47phox2/2
and gp91phox2/2 mice. J Immunol 168: 3974–3982.
20. Jackson SH, Gallin JI, Holland SM (1995) The p47phox mouse knock-out model
of chronic granulomatous disease. J Exp Med 182: 751–758.
21. Pollock JD, Williams DA, Gifford MA, Li LL, Du X, et al. (1995) Mouse model
of X-linked chronic granulomatous disease, an inherited defect in phagocyte
superoxide production. Nat Genet 9: 202–209.
22. Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM (2003)
Collaborative induction of inflammatory responses by dectin-1 and Toll-like
receptor 2. J Exp Med 197: 1107–1117.
23. Sadikot RT, Zeng H, Yull FE, Li B, Cheng DS, et al. (2004) p47(phox)
deficiency impairs NF-kappaB activation and host defense in Pseudomonas
pneumonia. J Immunol 172: 1801–1808.
24. DeLeo FR, Renee J, McCormick S, Nakamura M, Apicella M, et al. (1998)
Neutrophils exposed to bacterial lipopolysaccharide upregulate NADPH oxidase
assembly. J Clin Invest 101: 455–463.
25. Geiszt M, Leto TL (2004) The Nox family of NAD(P)H oxidases: host defense
and beyond. J Biol Chem 279: 51715–51718.
26. Lee IT, Wang SW, Lee CW, Chang CC, Lin CC, et al. (2008) Lipoteichoic acid
induces HO-1 expression via the TLR2/MyD88/c-Src/NADPH oxidase
pathway and Nrf2 in human tracheal smooth muscle cells. J Immunol 181:
5098–5110.
27. Papaiahgari S, Kleeberger SR, Cho HY, Kalvakolanu DV, Reddy SP (2004)
NADPH oxidase and ERK signaling regulates hyperoxia-induced Nrf2-ARE
transcriptional response in pulmonary epithelial cells. J Biol Chem 279:
42302–42312.
28. Sekhar KR, Crooks PA, Sonar VN, Friedman DB, Chan JY, et al. (2003)
NADPH oxidase activity is essential for Keap1/Nrf2-mediated induction of
GCLC in response to 2-indol-3-yl-methylenequinuclidin-3-ols. Cancer Res 63:
5636–5645.
29. Kensler TW, Wakabayashi N, Biswal S (2006) Cell Survival Responses to
Environmental Stresses Via the Keap1-Nrf2-ARE Pathway. Annu Rev
Pharmacol Toxicol.
30. Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA (2004) The Keap1-BTB
protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress
sensing by a Cul3-Keap1 ligase. Mol Cell Biol 24: 8477–8486.
31. Higa LA, Zhang H (2007) Stealing the spotlight: CUL4-DDB1 ubiquitin ligase
docks WD40-repeat proteins to destroy. Cell Div 2: 5.
32. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, et al. (2004) Oxidative
stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate
proteasomal degradation of Nrf2. Mol Cell Biol 24: 7130–7139.
33. Rachakonda G, Xiong Y, Sekhar KR, Stamer SL, Liebler DC, et al. (2008)
Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from
the ubiquitin ligase CUL3. Chem Res Toxicol 21: 705–710.
34. Liby K, Hock T, Yore MM, Suh N, Place AE, et al. (2005) The synthetic
triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme
oxygenase-1 and Nrf2/ARE signaling. Cancer Res 65: 4789–4798.
35. Juge N, Mithen RF, Traka M (2007) Molecular basis for chemoprevention by
sulforaphane: a comprehensive review. Cell Mol Life Sci 64: 1105–1127.
36. Ruddy MJ, Shen F, Smith JB, Sharma A, Gaffen SL (2004) Interleukin-17
regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts:
implications for inflammation and neutrophil recruitment. J Leukoc Biol 76:
135–144.
37. Liby KT, Yore MM, Sporn MB (2007) Triterpenoids and rexinoids as
multifunctional agents for the prevention and treatment of cancer. Nat Rev
Cancer 7: 357–369.
38. Thimmulappa RK, Lee H, Rangasamy T, Reddy SP, Yamamoto M, et al.
(2006) Nrf2 is a critical regulator of the innate immune response and survival
during experimental sepsis. J Clin Invest 116: 984–995.
39. Thimmulappa RK, Scollick C, Traore K, Yates M, Trush MA, et al. (2006)
Nrf2-dependent protection from LPS induced inflammatory response and
mortality by CDDO-Imidazolide. Biochem Biophys Res Commun.
40. Li N, Alam J, Venkatesan MI, Eiguren-Fernandez A, Schmitz D, et al. (2004)
Nrf2 is a key transcription factor that regulates antioxidant defense in
macrophages and epithelial cells: protecting against the proinflammatory and
oxidizing effects of diesel exhaust chemicals. J Immunol 173: 3467–3481.
41. Rangasamy T, Cho CY, Thimmulappa RK, Zhen L, Srisuma SS, et al. (2004)
Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced
emphysema in mice. J Clin Invest 114: 1248–1259.
42. Sakurai A, Nishimoto M, Himeno S, Imura N, Tsujimoto M, et al. (2005)
Transcriptional regulation of thioredoxin reductase 1 expression by cadmium in
vascular endothelial cells: role of NF-E2-related factor-2. J Cell Physiol 203:
529–537.
43. Zakkar M, Van der Heiden K, Luong le A, Chaudhury H, Cuhlmann S, et al.
(2009) Activation of Nrf2 in endothelial cells protects arteries from exhibiting a
proinflammatory state. Arterioscler Thromb Vasc Biol 29: 1851–1857.
44. Wei Y, Liu XM, Peyton KJ, Wang H, Johnson FK, et al. (2009) Hypochlorous
acid-induced heme oxygenase-1 gene expression promotes human endothelial
cell survival. Am J Physiol Cell Physiol 297: C907–915.
45. Zhu L, Pi J, Wachi S, Andersen ME, Wu R, et al. (2008) Identification of Nrf2-
dependent airway epithelial adaptive response to proinflammatory oxidant-
hypochlorous acid challenge by transcription profiling. Am J Physiol Lung Cell
Mol Physiol 294: L469–477.
46. Liby K, Voong N, Williams CR, Risingsong R, Royce DB, et al. (2006) The
synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation
and induces apoptosis in myeloma and lung cancer cells. Clin Cancer Res 12:
4288–4293.
47. Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, et al. (2007) The
synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent
lung cancer induced by vinyl carbamate in A/J mice. Cancer Res 67:
2414–2419.
48. Ji Y, Lee HJ, Goodman C, Uskokovic M, Liby K, et al. (2006) The synthetic
triterpenoid CDDO-imidazolide induces monocytic differentiation by activating
the Smad and ERK signaling pathways in HL60 leukemia cells. Mol Cancer
Ther 5: 1452–1458.
49. Li W, Khor TO, Xu C, Shen G, Jeong WS, et al. (2008) Activation of Nrf2-
antioxidant signaling attenuates NFkappaB-inflammatory response and elicits
apoptosis. Biochem Pharmacol 76: 1485–1489.
50. Liu GH, Qu J, Shen X (2008) NF-kappaB/p65 antagonizes Nrf2-ARE pathway
by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK.
Biochim Biophys Acta 1783: 713–727.
51. Lee DF, Kuo HP, Liu M, Chou CK, Xia W, et al. (2009) KEAP1 E3 ligase-
mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol
Cell 36: 131–140.
52. Zmijewski JW, Lorne E, Zhao X, Tsuruta Y, Sha Y, et al. (2009)
Antiinflammatory effects of hydrogen peroxide in neutrophil activation and
acute lung injury. Am J Respir Crit Care Med 179: 694–704.
53. Koay MA, Christman JW, Segal BH, Venkatakrishnan A, Blackwell TR, et al.
(2001) Impaired pulmonary NF-kappaB activation in response to lipopolysac-
charide in NADPH oxidase-deficient mice. Infect Immun 69: 5991–5996.
54. Kono H, Rusyn I, Yin M, Gabele E, Yamashina S, et al. (2000) NADPH
oxidase-derived free radicals are key oxidants in alcohol-induced liver disease.
J Clin Invest 106: 867–872.
55. Rusyn I, Yamashina S, Segal BH, Schoonhoven R, Holland SM, et al. (2000)
Oxidants from nicotinamide adenine dinucleotide phosphate oxidase are
involved in triggering cell proliferation in the liver due to peroxisome
proliferators. Cancer Res 60: 4798–4803.
56. Asehnoune K, Strassheim D, Mitra S, Kim JY, Abraham E (2004) Involvement
of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-
kappa B. J Immunol 172: 2522–2529.
57. Reynaert NL, van der Vliet A, Guala AS, McGovern T, Hristova M, et al.
(2006) Dynamic redox control of NF-kappaB through glutaredoxin-regulated S-
glutathionylation of inhibitory kappaB kinase beta. Proc Natl Acad Sci U S A
103: 13086–13091.
58. Fan J, Frey RS, Malik AB (2003) TLR4 signaling induces TLR2 expression in
endothelial cells via neutrophil NADPH oxidase. J Clin Invest 112: 1234–1243.
59. Gelderman KA, Hultqvist M, Pizzolla A, Zhao M, Nandakumar KS, et al.
(2007) Macrophages suppress T cell responses and arthritis development in mice
by producing reactive oxygen species. J Clin Invest 117: 3020–3028.
60. George-Chandy A, Nordstrom I, Nygren E, Jonsson IM, Postigo J, et al. (2008)
Th17 development and autoimmune arthritis in the absence of reactive oxygen
species. Eur J Immunol 38: 1118–1126.
61. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, et al. (2008) Inhibition of
dendritic cell differentiation and accumulation of myeloid-derived suppressor
cells in cancer is regulated by S100A9 protein. J Exp Med 205: 2235–2249.
62. Jancic C, Savina A, Wasmeier C, Tolmachova T, El-Benna J, et al. (2007)
Rab27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic
cell phagosomes. Nat Cell Biol 9: 367–378.
63. Sussan TE, Rangasamy T, Blake DJ, Malhotra D, El-Haddad H, et al. (2009)
Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette
smoke-induced emphysema and cardiac dysfunction in mice. Proc Natl Acad
Sci U S A 106: 250–255.
64. Chan JY, Kwong M (2000) Impaired expression of glutathione synthetic enzyme
genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein.
Biochim Biophys Acta 1517: 19–26.
65. Mardiney M, 3rd, Jackson SH, Spratt SK, Li F, Holland SM, et al. (1997)
Enhanced host defense after gene transfer in the murine p47phox- deficient
model of chronic granulomatous disease. Blood 89: 2268–2275.
NADPH Oxidase and Inflammation
PLoS ONE | www.plosone.org 14 March 2010 | Volume 5 | Issue 3 | e9631